A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
Condition: Diabetic Neuropathy, Painful
MeSH terms: Neuralgia; Diabetic Neuropathies
Intervention: Duloxetine; Placebo
Intervention description: 30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period; Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
Intervention MeSH terms: Duloxetine Hydrochloride
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 405.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Diabetic Peripheral Neuropathic Pain

Summary:

      The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once
      daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as
      measured by the weekly mean of the daily pain scores recorded in the participant's diary in
      participants with diabetic peripheral neuropathic pain.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Present with pain due to bilateral peripheral neuropathy

               -  Participants must have pain caused by Type 1 or Type 2 diabetes mellitus

               -  Pain must begin in the feet with relatively symmetrical onset

               -  Daily pain should be present for at least 6 months

               -  Diagnosis must be confirmed by a score of at least 3 on the Michigan Neuropathy
                  Screening Inventory (MNSI)

          -  Females must test negative for a serum pregnancy test at Screening. Females of
             child-bearing potential (who are not surgically sterilized and between menarche and 1
             year postmenopause) must agree to use a medically acceptable and reliable means of
             birth control, during the study and for 1 month following the last study dose.

          -  Stable glycemic control as assessed by a physician investigator and a glycosylated
             hemoglobin (HbA1c) <12% before randomization

          -  Score of greater than or equal to 4 on the Brief Pain Inventory (BPI) 24-hour average
             pain item at Screening.

          -  Full completion of the daily diaries for at least 80% of the days between the second
             and third time you come to the hospital (Screening).

        Exclusion Criteria:

          -  Currently enrolled in, or discontinued within the last 30 days from, a clinical trial
             involving an investigational drug or device or off-label use of a drug or device, or
             concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study

          -  Current (less than or equal to 1 year) Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (DSM-IV) Axis I diagnosis of major depressive disorder,
             dysthymia, anxiety disorders (excluding phobias), alcohol or eating disorders as
             determined by the Mini-International Neuropsychiatric Interview (MINI) or a previous
             diagnosis

          -  DSM-IV diagnosis of mania, bipolar disorder, or psychosis determined either by
             participant history or by diagnosis using specific MNSI modules

          -  Serious or unstable cardiovascular, hepatic, renal, respiratory, or hematologic
             illness, symptomatic peripheral vascular disease, or other medical condition or
             psychological conditions that in the opinion of investigator would compromise
             participation or be likely to lead to hospitalization during the course of the study.

          -  At Screening alanine transaminase (ALT) greater than 2 times upper limit of normal
             (ULN), based on central laboratory reference ranges times ULN, based on central
             laboratory reference ranges

          -  Prior renal transplant, current renal dialysis, or serum creatinine laboratory value
             >1.5 times ULN, based on central laboratory reference ranges at Screening.

          -  Historical exposure to drugs known to cause neuropathy, or a history of a medical
             condition, including pernicious anemia and hypothyroidism, that could have been
             responsible for neuropathy

          -  Pain that cannot be clearly differentiated from or conditions that interfere with the
             assessment of the diabetic neuropathy pain. Examples of painful conditions that could
             be confused with diabetic neuropathy pain include peripheral vascular disease,
             neurological disorders unrelated to diabetic neuropathy, skin condition in the area of
             the neuropathy that could alter sensation, other painful conditions

          -  Participants who have previously completed or withdrawn from this study or have been
             previously treated with duloxetine, including participants who participated in study
             F1J-MC-HMEQ (NCT00408993), even those in the placebo arm

          -  Participants taking excluded medications that cannot be stopped at Screening

          -  Treatment with a monoamine oxidase inhibitor (MAOI) or fluoxetine within 30 days of
             the third Screening

          -  Participants with a positive Hepatitis B surface antigen and/or Hepatitis C antibody
             are to be excluded if they have any of the following:

               -  Hepatic dysfunction as determined by the investigator or

               -  Clinical manifestations of liver disease within the previous year such as
                  unexplained pruritus, unexplained dark urine, jaundice, unexplained right upper
                  quadrant tenderness, unexplained "flu-like" symptoms or

               -  Aspartate transaminase (AST), ALT, or bilirubin above the normal reference range.